4//SEC Filing
Nolan Sean P. 4
Accession 0001209191-23-058971
CIK 0001806310other
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 4:46 PM ET
Size
5.9 KB
Accession
0001209191-23-058971
Insider Transaction Report
Form 4
Nolan Sean P.
DirectorChief Executive Officer
Transactions
- Award
Employee Stock Option (right to buy)
2023-12-14+466,550→ 466,550 totalExercise: $0.70Exp: 2033-12-14→ Common Stock (466,550 underlying)
Footnotes (1)
- [F1]The compensation committee of the board of directors of the Issuer certified achievement of certain performance criteria such that 70% of the option shares subject to the performance-based stock option award were earned. The shares underlying the earned potion of the option shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
Documents
Issuer
Taysha Gene Therapies, Inc.
CIK 0001806310
Entity typeother
Related Parties
1- filerCIK 0001569926
Filing Metadata
- Form type
- 4
- Filed
- Dec 17, 7:00 PM ET
- Accepted
- Dec 18, 4:46 PM ET
- Size
- 5.9 KB